From Lab to Market

Research Partners

We establish research collaborations with the internationally reputable research institutions to assay, verify and optimise our drug candidates.

Hence, we can have multiple ongoing pipelines of novel drug R&D. By the completion of pre-clinical stage, our drugs will have the "investigational new drug" status.

Commercialisation Partners

We will license out the INDs to companies for further development and commercialisation. For example:

  • for clinical use, we can licence IND to pharmaceutical for the further drug development.

  • for preventives, commercial party can develop as supplements to avoid certain health conditions.

Strategic Investors

We seek to raise fund from strategic investors (whether direct equity investment or debt instrument) with the intention to accelerate the development and commercialisation of multiple pipelines for both human drugs and animal drugs. 

For Animal Health, we aim to release our first product by Q2 of 2024, targeting cats infected by FIP. 

Looking for new drug candidates?

Our compound library may have just the solutions that you are searching for.

Please feel free to Contact Us and we can chat over a cuppa or video conference.